- Home
- CDLR vs CGON Comparison
CDLR vs CGON Comparison
Compare CDLR & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDLR
- CGON
- Stock Information
- Founded
- CDLR 2008
- CGON 2010
- Country
- CDLR Denmark
- CGON United States
- Employees
- CDLR N/A
- CGON N/A
- Industry
- CDLR
- CGON
- Sector
- CDLR
- CGON
- Exchange
- CDLR Nasdaq
- CGON NYSE
- Market Cap
- CDLR 1.9B
- CGON 2.1B
- IPO Year
- CDLR N/A
- CGON 2024
- Fundamental
- Price
- CDLR $19.79
- CGON $26.58
- Analyst Decision
- CDLR
- CGON Strong Buy
- Analyst Count
- CDLR 0
- CGON 10
- Target Price
- CDLR N/A
- CGON $64.44
- AVG Volume (30 Days)
- CDLR 90.0K
- CGON 811.0K
- Earning Date
- CDLR 08-26-2025
- CGON 08-07-2025
- Dividend Yield
- CDLR N/A
- CGON N/A
- EPS Growth
- CDLR N/A
- CGON N/A
- EPS
- CDLR 0.31
- CGON N/A
- Revenue
- CDLR $319,011,025.00
- CGON $662,000.00
- Revenue This Year
- CDLR $106.55
- CGON N/A
- Revenue Next Year
- CDLR $92.34
- CGON $25,206.93
- P/E Ratio
- CDLR $18.42
- CGON N/A
- Revenue Growth
- CDLR 171.33
- CGON 224.51
- 52 Week Low
- CDLR $17.37
- CGON $14.80
- 52 Week High
- CDLR $28.75
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- CDLR 44.64
- CGON 56.82
- Support Level
- CDLR $19.64
- CGON $25.81
- Resistance Level
- CDLR $20.27
- CGON $27.28
- Average True Range (ATR)
- CDLR 0.43
- CGON 1.00
- MACD
- CDLR -0.16
- CGON 0.00
- Stochastic Oscillator
- CDLR 24.54
- CGON 83.08
About CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.